

May 14, 2026

To,  
Dy. General Manager  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001

To,  
The Manager – Listing,  
National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 543322

Ref: Scrip Name: ALIVUS

Dear Sirs,

**Sub: Press Release**

Pursuant to regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Press Release of the Company for the fourth quarter and year ended March 31, 2026.

You are requested to take the same on record.

Thanking You.

Yours faithfully,  
**For Alivus Life Sciences Limited**  
(formerly Glenmark Life Sciences Limited)

**Rudalf Corriea**  
**Company Secretary and Compliance Officer**  
Encl.: As above

**Alivus Life Sciences Limited** (formerly Glenmark Life Sciences Limited)

**Corporate Office:**

Technopolis Knowledge Park, A wing, Office No. 401 to 407,  
4th Floor, Mahakali Caves Road, Andheri ( E), Mumbai – 400093

**Registered Office:**

Plot No 170-172, Chandramouli Industrial Estate  
Mohol Bazarpath, Solapur 413 213, India

T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com



## PRESS RELEASE

For Immediate dissemination



### **Alivus Life Sciences delivers a strong revenue growth of 6.9% YoY for FY26**

#### **EBITDA Margins were 33.6%, up 360 bps YoY with 19.6% growth YoY**

**Mumbai, May 14, 2026: Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited),** a leading developer and manufacturer of select, high-value, non-commoditized, Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas, today announced its financial results for the quarter and year ended March 31, 2026.

For FY26, Alivus registered a Revenue from operations of Rs. 25,518 Mn, a growth of 6.9% YoY. For Q4FY26, Revenue from operations was Rs. 6,891 Mn, a growth of 6.1% YoY.

For FY26, EBITDA was at Rs. 8,577 Mn, a growth of 19.6% YoY. EBITDA margins were at 33.6%, up 360 bps YoY.

For Q4FY26, EBITDA was at Rs. 2,373 Mn, a growth of 13.8% YoY. EBITDA margins were at 34.4%, up 230 bps YoY.

PAT for FY26 stood at Rs. 5,645 Mn, a growth of 16.2% YoY and PAT margins were at 22.1%, up 180 bps YoY.

PAT for Q4FY26 stood at Rs. 1,627 Mn, a growth of 14.7% YoY and PAT margins were at 23.6%, up 180 bps YoY.

During FY26, the company generated a strong free cash flow of Rs. 2,590 Mn leading to Cash and Cash Equivalents (including short term investments) of Rs. 7,824 Mn as of March 31, 2026.

**Commenting on the company's performance Dr. Yasir Rawjee, MD & CEO, Alivus Life Sciences Limited said,** *"The past two years under Nirma's ownership have been deeply fulfilling – a period of transition and evolution that has strengthened the foundation of the business and positioned us decisively for the next phase of sustainable growth.*

*Coming to our results, FY26 reflected a clear improvement in our operating performance. Revenue grew 6.9% year-on-year, supported by growth in non-GPL business of 13%, which resulted in EBITDA growth of 19.6%. Encouragingly, the CDMO business delivered the turnaround we had planned in the second half, closing the year with 18% YoY growth. We also witnessed healthy momentum across key geographies like India, Europe, ROW, Japan and LATAM, while the GPL business de-grew by 4.9%.*

*For FY27, we remain confident of delivering high single-digit revenue growth, with margins sustained above 30%, supported by improving operating leverage and a rising contribution from new products."*

**Tushar Mistry, CFO, Alivus Life Sciences Limited said,** *"We continued our strong growth momentum in Q4FY26, delivering 6.1% year-on-year revenue growth. We ended FY26 with 6.9% growth. The performance was broad-based, with contributions from almost all regions. At Alivus, we remain focused on profitable growth, reflected in the improvement in both, our Gross and EBITDA margins during the quarter.*

*For the full year, we reported EBITDA margins of 33.6%, exceeding our guided range of 30–32%, driven by a favourable product mix and disciplined control over operating expenses. The year has ended with strong operating cash flows, providing us ample flexibility to support our growth initiatives while maintaining a healthy, debt-free balance sheet."*

## PRESS RELEASE

For Immediate dissemination



### Additional Highlights:

- DMF / CEP filings continue across major markets, taking the total cumulative filings to 611 as on March 31, 2026
- The HP API portfolio has 28 APIs in the active grid with 12 products are validated, seven products are in advanced stages of development, remaining nine products progressing through lab development stages

### Capex Update:

- Solapur – Phase 1 and 1.1 construction work is in progress for 465 KL capacity
- To lead the future, we have acquired land in Taloja (Navi Mumbai) admeasuring 10,000 square meter to establish a state-of-the-art R&D centre, designed to advance complex chemistry and oncology research. The centre will focus on flow chemistry, complex products, particle engineering and green chemistry, strengthening our pipeline across key therapeutic areas. Construction work in our new R&D facility has commenced.

### About Alivus Life Sciences Ltd (ALIVUS)

**Alivus Life Sciences Limited** (Formerly Glenmark Life Sciences Limited) (BSE: 543322, NSE: ALIVUS), is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. The company is increasingly providing CDMO services to a range of multinational and specialty pharmaceutical companies. It has a diversified portfolio of 176 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World (RoW).

The company's four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh with a total installed capacity of 1424 KL, which are regularly inspected by global regulators such as USFDA, PMDA (Japan) and EDQM (Europe). Alivus Life Sciences is listed on BSE and NSE.

Learn more about Alivus Life Sciences Limited on <https://www.alivus.com>

#### For any further queries please contact:

**Soumi Rao | Senior General Manager – Corporate Communications**

Email: [Soumi.Rao@alivus.com](mailto:Soumi.Rao@alivus.com)

Mobile: 98701 96931

**Ernst & Young LLP – Investor Relations**

**Diwakar Pingle**

Email: [Diwakar.Pingle@in.ey.com](mailto:Diwakar.Pingle@in.ey.com)

**Runjhun Jain**

Email: [Runjhun.Jain1@in.ey.com](mailto:Runjhun.Jain1@in.ey.com)

**Sneha Salian**

Email: [Sneha2.Salian@in.ey.com](mailto:Sneha2.Salian@in.ey.com)